Cargando…
A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment
Multiple myeloma is an incurable and slow growing plasma cell neoplasm. The introduction of new drugs has increased the number of treatment options. Bortezomib, the first-in-class proteasome inhibitor, has been shown to have a significant antitumor activity in the treatment of relapse/refractory pat...
Autores principales: | Bae, Soo-Young, Ahn, Jae-Sook, Yang, Deok-Hwan, Kim, Yeo-Kyeoung, Min, Jung-Joon, Song, Ho-Chun, Bom, Hee-Seung, Jeong, Yong Yeon, Kim, Hyeoung-Joon, Lee, Je-Jung |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072187/ https://www.ncbi.nlm.nih.gov/pubmed/21475598 http://dx.doi.org/10.1159/000324920 |
Ejemplares similares
-
Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
por: Jung, Sung-Hoon, et al.
Publicado: (2012) -
Anti-Angiogenic Treatment (Sunitinib) for Disseminated Malignant Haemangiopericytoma: A Case Study and Review of the Literature
por: Delgado, M., et al.
Publicado: (2011) -
Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014) -
Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016) -
Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
por: Cervigón-González, Iván, et al.
Publicado: (2011)